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Abstract: A non-targeted strategy to simultaneously screen for over 100 lipid mediators from
ω-6 ARA and ω-3 EPA and DHA fatty acids is presented. The method based on an extensive
study of fragmentation patterns obtained by SPE-LC-MS/MS analysis-provided fingerprints to
comprehensively elucidate and identify lipid mediators in biological samples. Many of these
metabolites are associated to metabolic disorders, inflammatory, immune and oxidative stress. The
methodology consisted of a three-step procedure. (1) SPE extraction of compounds from plasma and
adipose tissue was followed by LC-MS/MS analysis operating in full scan mode. The methodology
was validated for a group of 65 metabolites using standards. SPE recoveries ranged from 29–134% and
matrix effect from 10–580%. LOD and LOQ ranged from 0.01 to 1765 ng/mL and 0.03 to 5884 ng/mL
respectively, similarly than current analytical strategies based on MRM mode. (2) An extensive study
of the mass spectra of a wide range of compounds was done to stablish a specific fragmentation pattern.
Interestingly, illustrative fragmentations and new specific transitions to identify EPA and DHA lipid
mediators have been innovatively established. (3) After analysis, 30 lipid mediators were tentatively
identified in plasma and 35 in adipose tissue of rats according to the pre stablished fragmentation
patterns. The hypothetical identification of compounds was validated by using reference standards.
Around 85–90% of proposed identifications were correctly assigned and only 4 and 3 identifications
failed in adipose tissue and plasma, respectively. The method allowed the identification of these
metabolites without losing information by the use of predefined ions list. Therefore, the use of full
scan mode together with the study of fragmentation patterns provided a novel and stronger analytical
tool to study the complete profile of lipid mediators in biological samples than the analysis through
MRM based methods. Importantly, no analytical standards were required at this qualitative screening
stage and the performance and sensitivity of the assay were very similar to that of a MRM method.
Keywords: lipid mediators;ω-3 andω-6 PUFAs; non-targeted analysis; fragmentation patterns
1. Introduction
Lipid mediators have drawn much attention in clinical studies because they are a family of
molecules that play a key role in the progression of inflammation and metabolic disorders [1].
They exhibit a large number of physiological effects in almost every organ system because of
highly coordinated active processes including cellular signaling and transcription factors regulation,
modulation of metabolic pathways and inflammation resolution, [2]. The production of these bioactive
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compounds is mediated by cyclooxygenases, lipoxygenases, cytochrome P450 mono- oxygenases, and
non-enzymatic pathways [3] from the mainω-6 andω-3 PUFAs as it is shown in Figure 1a,b. A very
large number of isomeric compounds from different families can be produced. Specific examples
include the families of PGs, IsoPs, TXs, and LTs which have been described as pro-inflammatory
substances [1,4]. The most studied compounds derived from ARA are PGE2, PGF1α, PGF2α, TXA2 and
8iso-PGF2α, which have been associated with the chronic inflammatory stage of hypercholesterolemia,
liver cirrhosis, myocardial reperfusion, type-2 diabetes, obesity, atherosclerosis, cancer, and CVD [5–8].
On the other hand, the corresponding metabolites produced from EPA and DHA have been suggested
as less harmful compounds than the ω-6 ones [9,10]. Oxygenated lipid mediators derived from
EPA and DHA, have been suggested one of the most efficient mechanisms to stop inflammation in a
highly coordinated, active process [11]. Several works indicates that these mediators can resolve acute
inflammatory responses with minimal damage to the surrounding tissue in a variety of inflammation
situations [12,13]. Molecules like LXs [14], epoxides [15], and the recently discovered Rvs, PDs,
and MaRs [16]. have been associated with the resolution of inflammation in CVD [6], arthritis [17],
asthma [18], cancer [19,20], or Alzheimer [21,22].
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Figure 1. (a): Cascade of formation of lipid mediators fromω-6 LA, DGLA and ARA. (b): Cascade of
formation of lipid mediators fromω-3 ALA, EPA, and DHA.
The simultaneous analysis of the different families is a tough challenge, mainly because of their low
physiological levels and the low stability [23], the matrix background interferences, and the large number
of isomers with similar physicochemical properties and mass spectra that hinder their chromatography
resolution and MS/MS identification [24]. Therefore, a highly sensitive and selective analytical
procedure is essential to comprehensively study these lipid classes. Mass spectrometry has played a
central role in quantitative assays for most of lipid mediators but also in their structural elucidation.
While some progress has been made on the decomposition behavior of ω-6 metabolites, there
is a great deal more to understand ω-3 metabolism. For many years, GC-MS was the method of
choice for lipids mediators [25]; nevertheless, the widespread LC-MS coupled with high-sensitivity
ESI has provided a new approach for quantification, minimizing sample preparation requirements
and particularly avoiding derivatization reactions [26]. Commonly, LC-MS/MS procedures follow
MRM targeted analysis. Methods available in literature range from the simultaneously analysis of a
few compounds [27,28] to more than one hundred [29–31]. Although these assays are sensitive and
selective and cover a large number of metabolites, they are limited due to the trade-off between the
decreases of sensitivity and the increase of the number of monitored compounds. In addition, MRM
is limited to the analysis of a specific targeted group of compounds that operator must pre-define
prior to the analysis. Therefore, the method is not suitable for a screening of the whole family of lipid
mediators in biological samples unless a big number of expensive analytical standards are used to
stablish the MS/MS transitions list.
Non-targeted LC-MS/MS strategies register the full mass spectra of each group of compounds
having the same parent mass. Then, this method favors the structural elucidation of metabolites
enhancing the identification of co-eluting isomers. Moreover, this procedure allows the identification
of many lipid mediators based on the study of fragmentation patterns without preselecting a group
of compounds that might be or not in samples. Few works proposing screening methods of MS/MS
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have been found in literature to analyze lipid mediators. One of them was performed by Masoodi
et al. [24] who validated an analytical methodology for the screening of lipid mediators combining
the high mass resolution authority of an Orbitrap instrument and the study of MS/MS transitions. In
our study, we achieved good identifications by using a LIT and suggested new specific transitions to
identify lipid mediators.
The aim of this research was to develop a sensitive and selective non-targeted MS/MS method that
allows the simultaneous screening of more than 100 lipid mediators in a single run. The procedure is
based on the exhaustive interpretation of the mass spectra obtained. Firstly, SPE extraction of analytes
from plasma and adipose tissue was carried out by and the procedure was validated for most of
the different families of lipid mediators. 65 analytical standards of the representative metabolites
were used for recovery experiments. Secondly, the mass spectra of the main ω-6 and ω-3 lipid
mediators representative of the different families were exhaustive interpreted in order to systematize a
pattern of diagnostic fragments for each compound. Then, a 24 min LC-MS/MS method operating
in full scan mode and including the parent mass of the main families of compounds was optimized.
Chromatographic gradient and mass spectrometry parameters were set for this representative group
of 65 analytical standards. Finally, biological samples were analyzed and unknown peaks were
tentatively identified matching specific MS/MS transitions with fragmentation patterns previously
selected. Identifications were further validated by using analytical standards. This work provides an
extensive interpretation and compilation of distinctive fragmentation patterns of lipid mediators that
allows the use of non-targeted MS/MS strategies for the non-limited screening of biological samples.
2. Results and Discussion
2.1. SPE-LC-MS/MS Validation
The complete SPE-LC-MS/MS methodology applied for the extraction and analysis of lipid
mediators. was validated with 65 standards representative of the main groups of compounds. The
retention times, the selected MS/MS transitions, R2 linearity, repeatability, reproducibility, LODs, and
LOQs of these 65 analytical standards are summarized in Table 1.
Table 1. Retention times. MS/MS quantification transitions (m/z). Linearity by least-squares linear
regression (1 to 1000 ng/mL except for PUFAs: 0.1 to 50 µg/mL). Intra-day repeatability (n = 4) and
inter-day reproducibility (n = 4) of LC-MS assays at three concentration levels (1-50-1000 ng/mL except















1 50 1000 1 50 1000
15-HEPE 11.96 317 > 247 0.9996 1 1 3 11 1 3 0.37 1.24
18-HEPE 11.55 317 > 259 0.9999 7 1 1 7 2 3 0.18 0.58
12-HEPE 12.62 317 > 208 1.000 3 3 3 6 3 7 0.01 0.03
5-HEPE 14.17 317 > 115 0.9999 3 0 2 7 2 8 0.37 1.25
11-HEPE 12.13 317 > 195 0.9995 8 0 1 11 1 6 0.13 0.43
11-HETE 15.32 319 > 167 0.9968 4 4 8 18 8 9 0.06 0.21
5-HETE 15.96 319 > 115 0.9807 13 9 2 14 7 2 0.07 0.24
12-HETE 15.48 319 > 179 0.9991 4 3 7 7 7 8 0.03 0.11
15-HETE 14.83 319 > 219 0.9962 12 2 4 11 10 4 0.07 0.25
20-HETE 13.69 319 > 245 0.9988 4 2 2 11 4 4 0.53 1.76
4-HDoHE 16.08 343 > 281 0.9997 2 10 9 14 8 9 0.04 0.15
17-HDoHE 15.19 343 > 245 0.9998 5 3 2 10 4 5 0.29 0.96
14-HDoHE 15.43 343 > 205 0.9907 3 6 5 6 10 8 0.10 0.33
11-HDoHE 15.67 343 > 149 0.9985 10 6 6 9 8 5 0.07 0.25
15-OxoETE 13.69 317 > 113 0.9999 13 3 1 13 8 2 1.58 5.27
12-OxoETE 14.83 317 > 153 0.9944 nd 3 3 nd 71 27 1.21 4.03
5-OxoETE 15.95 317 > 203 0.9974 7 9 5 14 8 4 0.11 0.38
15-HpEPE 11.93 333/315 > 271 0.9986 nd 2 2 nd 14 3 0.59 1.95
















1 50 1000 1 50 1000
12-HpEPE 12.42 333/315 > 271 0.9996 10 1 1 10 23 9 0.29 0.95
12-HpETE 15.39 335/317 > 153 0.9998 15 0 3 15 29 3 0.50 1.65
5HpETE 15.86 335/317 > 155 0.9620 nd 13 7 nd 16 9 6.48 21.59
15-HpETE 14.83 335/317 > 113 0.9991 nd 3 1 nd 9 1 17.65 58.84
17-HpDoHE 15.12 359/341 > 297 0.9998 13 1 3 11 5 3 1.05 3.51
14.15-DiHETE 8.58 335 > 207 0.9998 9 1 1 12 1 1 0.53 1.78
5.15-DiHETE 7.93 335 > 235 0.9983 10 0 5 15 17 8 0.18 0.61
5.6-DiHETE 10.56 335 > 145 0.9994 1 3 2 1 9 5 0.95 3.16
11.12-DiHETrE 10.68 337 > 167 0.9988 3 1 3 8 3 2 0.05 0.16
8.9-DiHETrE 11.66 337 > 185 0.9999 5 2 1 7 4 8 0.17 0.55
14.15-DiHETrE 10.03 337 > 207 0.9989 7 2 4 19 3 4 0.12 0.39
5.6-DiHETrE 13.87 337 > 145 0.9988 5 3 2 7 4 3 0.10 0.35
19.20-DiHDPA 10.60 361 > 273 0.9996 5 0 1 9 4 4 0.17 0.55
17.18-DiHETE 8.50 335 > 247 0.9989 2 3 2 13 6 4 0.46 1.54
7.17-hydroxiDPA 8.22 361 > 263 1.000 14 2 3 14 11 9 0.43 1.45
11.12-EpETrE 16.12 319 > 179 0.9890 13 9 11 11 7 9 0.17 0.58
8.9-EpETrE 16.20 319 > 155 0.9516 12 12 11 23 20 9 0.13 0.42
14.15-EpETrE 15.80 319 > 219 0.9920 11 15 7 11 13 6 0.26 0.87
5.6-EpETrE 16.28 319 > 191 0.9950 15 12 5 15 65 29 0.41 1.38
17.18-EpETE 13.85 317 > 259 0.9999 2 1 6 11 8 9 0.19 0.63
11.12-EpETE 15.07 317 > 179 0.9969 4 3 7 9 6 6 0.24 0.81
14.15-EpETE 14.83 317 > 207 0.9987 6 2 4 15 12 11 0.27 0.91
8.9-EpETE 15.32 317 > 155 0.9998 19 3 6 13 5 5 0.50 1.67
19.20-EDP 15.84 343 > 241 0.9945 11 5 6 18 10 14 0.30 0.99
10.11-EDP 16.08 343 > 153 0.9976 2 6 8 10 19 12 0.14 0.45
16.17-EDP 16.00 343 > 233 0.9487 11 7 3 16 5 7 0.24 0.79
7.8-EDP 16.24 343 > 141 0.9918 7 6 7 24 20 11 0.30 0.99
13.14-EDP 16.00 343 > 193 0.9934 14 14 12 15 13 22 0.21 0.69
LTB4 8.50 335 > 195 0.9993 4 3 4 17 17 11 0.08 0.27
LTC4 9.05 624 > 272 0.9984 10 3 6 11 5 5 0.20 0.67
PGB2 6.62 333 > 175 0.9999 13 2 1 12 7 9 0.26 0.86
PGJ2 6.62 333 > 175 0.9975 22 3 4 22 11 8 0.75 2.51
PGE2 5.64 351 > 251 0.9997 nd 4 3 nd 4 2 3.88 12.95
PGD2 5.64 351 > 251 0.9979 nd 7 2 2 5 2 4.33 14.45
PGD3 5.14 349 > 313 0.9985 1 1 2 1 1 2 0.10 0.30
PGE3 5.14 349 > 313 0.9985 1 1 2 1 1 2 0.10 0.30
8iso-PGF3α 4.97 351 > 253 0.9960 7 4 3 14 14 16 0.22 0.73
8iso-PGF2α 5.47 353 > 299 0.9936 8 3 2 8 3 2 0.06 0.20
MaR-1 8.09 359 > 177 0.9998 5 2 5 9 4 4 0.21 0.71
PDx 7.67 359 > 153 0.9984 3 1 3 3 3 4 0.05 0.16
TXB3 5.05 367 > 195 0.9981 1 3 2 10 4 2 0.06 0.21
RvD1 6.00 375 > 141 0.9958 1 1 2 1 1 2 0.02 0.07
RvD2 5.56 375 > 141 0.9988 4 2 2 9 7 3 0.12 0.39
12-HETE-d8 15.43 326 > 183 5 6 4 5 6 4 0.002 0.006
ARA 17.34 303 > 259 0.9677 7 6 12 7 11 11 1.96 6.53
EPA 16.92 301 > 257 0.9923 13 15 8 11 16 12 0.28 0.93
DHA 17.27 327 > 283 0.9925 10 13 11 7 10 15 0.18 0.59
The linear dynamic range of response was observed between 1 ng/mL and 1000 ng/mL for each
compound. R2 values were higher than 0.99 for most compounds. LOD and LOQ values ranged
between 0.01 to 17.65 ng/mL and 0.03 to 58.84 ng/mL, respectively, and these values were in agreement
with those previously reported in the literature [16,28,32]. The instrumental intra-day repeatability
and inter-day reproducibility at the low, intermediate and high concentration ranges (n = 4) showed
acceptable precision, with values below 15 %RSD for almost all compounds.
Finally. Table 2 summarizes the repeatability of the entire optimized method, the global recovery,
SPE recovery and matrix effects for spiked samples. The %RSD obtained in the different set of recovery
experiments ranged between 0.01–21 in plasma and 0.4–67 in adipose tissue and they were slightly
higher than instrumental %RSD. Thus, the precision of the entire protocol is mainly controlled by
the sample extraction rather than by the mass analyzer. Global recoveries ranged between 7–489%
in plasma and 18–442% in adipose tissue and recoveries of the SPE step were around 100 ± 15%
for most of the compounds in plasma and were lower in adipose tissue, ranging between 40–115%.
The main parameter that affected the global recovery of the method was the matrix effect. It ranged
between 10–494% in plasma samples and between 21–580% in adipose tissue. There might be multiple
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reasons for the loss/gain of signal in the mass spectrometer. Among the main causes stand out the ion
suppression and the overproduction of the [M-H]- precursor ions of analytes in the ESI source due to
co-eluting substances from the matrix. Matrix effects were considerable for some metabolites eluting
in the last part of the chromatography.
Table 2. Repeatability of the SPE-LC-MS assay. Global Recovery (SPE-LC-MS). Extraction recovery (SPE)
and matrix effect (LC-MS) for spiked plasma and adipose tissue samples (n = 3). n.e. (non-evaluated).
Compound
%RSD (n = 3) %Global Recovery %SPE Recovery %Matrix Effect
Plasma Adipose Plasma Adipose Plasma Adipose Plasma Adipose
15-HEPE 9 9 91 87 102 88 88 99
18-HEPE 7 6 85 81 107 95 80 85
12-HEPE 10 6 84 94 103 94 82 100
5-HEPE 8 7 84 64 107 90 79 71
11-HEPE 2 6 93 86 115 94 81 92
11-HETE 18 3 75 91 93 96 73 95
5-HETE 15 11 144 155 113 115 199 122
12-HETE 3 6 91 67 97 109 86 58
15-HETE 5 12 86 81 101 108 85 75
20-HETE 9 9 95 92 107 101 89 91
4-HDoHE 7 5 489 442 101 97 494 580
17-HDoHE 2 9 84 78 111 78 76 101
14-HDoHE 9 10 85 66 101 95 84 70
11-HDoHE 8 0 81 81 108 91 75 84
15-OxoETE 7 8 87 54 104 92 84 59
12-OxoETE 3 14 94 52 107 80 90 65
5-OxoETE 15 6 379 294 101 72 344 409
15-HpEPE 2 9 17 22 87 89 10 25
12-HpEPE 0 6 7 18 29 60 25 33
12-HpETE 4 21 27 28 92 90 26 30
5-HpETE 16 11 53 71 64 105 83 67
15-HpETE 0 23 37 44 57 71 66 67
17-HpDoHE 3 12 24 19 86 94 14 21
14.15-DiHETE 7 10 95 90 92 93 103 97
5.15-DiHETE 4 8 92 86 99 94 94 92
5.6-DiHETE 12 8 61 95 75 96 82 99
11.12-DiHETrE 3 12 69 35 82 41 83 83
8.9-DiHETrE 7 18 82 36 92 42 90 84
14.15-DiHETrE 2 7 59 35 91 40 64 85
5.6-DiHETrE 6 10 83 34 93 42 88 80
19.20-DiHDPA 1 15 78 37 91 41 85 87
17.18-DiHETE 1 52 87 59 99 63 88 89
7.17-hydroxiDPA 1 27 74 33 89 42 82 79
11.12-EpETrE 1 19 447 142 107 45 397 341
8.9-EpETrE 3 30 334 121 107 45 309 266
14.15-EpETrE 9 29 179 41 114 38 143 145
5.6-EpETrE 7 20 228 104 103 38 211 276
17.18-EpETE 2 22 86 35 100 50 84 72
11.12-EpETE 3 13 78 37 102 45 76 80
14.15-EpETE 0 16 70 36 100 44 70 81
8.9-EpETE 0 21 69 34 101 47 69 69
19.20-EDP 4 10 185 51 134 45 129 110
10.11-EDP 21 30 394 159 105 46 396 346
16.17-EDP 2 17 469 194 111 53 404 333
7.8-EDP 10 8 238 114 108 50 228 237
13.14-EDP 1 19 471 191 109 50 433 336
LTB4 8 7 82 52 98 96 78 54
LTC4 0 0 0 0 60 65
PGB2 2 6 97 68 115 93 85 73
PGJ2 5 9 81 67 97 88 83 76
PGE2 8 8 81 82 101 90 80 91
PGD2 7 67 128 46 109 94 118 51
PGD3/PGE3 10 n.e. 94 n.e. 94 n.e. 100 n.e.
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Table 2. Cont.
Compound
%RSD (n = 3) %Global Recovery %SPE Recovery %Matrix Effect
Plasma Adipose Plasma Adipose Plasma Adipose Plasma Adipose
8iso-PGF3α 14 11 45 33 50 43 103 79
8iso-PGF2α 8 n.e. 86 n.e. 85 n.e. 102 n.e.
MaR-1 3 1 108 73 124 111 87 60
PDx 12 5 97 75 102 103 96 74
TXB3 7 11 48 36 61 55 78 68
RvD1 12 n.e. 85 n.e. 75 n.e. 89 n.e.
RvD2 10 9 63 56 98 86 64 65
12-HETE-d8 15 6 73 60 91 94 76 64
ARA 4 n.e. 100 n.e. 111 n.e. 90 n.e.
EPA 6 n.e. 98 n.e. 106 n.e. 93 n.e.
DHA 3 n.e. 88 n.e. 123 n.e. 71 n.e.
2.2. Fragmentation Patterns Through the Analysis of Mass Spectra of Lipid Mediators
Here it is presented an extensive study of the MS/MS spectra of over 100 ARA. EPA and DHA lipid
mediator that allowed determining specific fragmentation patterns useful for identification purposes.
Most of MS/MS spectra and/or stereochemical structure of compounds were obtained from the LIPID
MAPS database (https://www.lipidmaps.org). In the next paragraphs, fragmentation patterns for the
different families of lipid mediators are discussed and specific cleavages aimed to identify the different
chemical isomers are suggested. Most of the collision-induced decompositions suggested have been
also discussed by previous published works. Specially, those compounds derived from the metabolism
of ARA [33]. However, to the best of our knowledge, illustrative fragmentations of EPA and DHA
derivatives some are innovatively proposed in this work. In addition to the study of mass spectra,
the main difficulties in the identification of some isomers are also pointed out, as are common false
positive identifications and so on.
2.2.1. Monohydroxides
A common fragmentation pattern was observed for monohydroxides of ARA (HETEs), EPA
(HEPEs) and DHA (HDoHEs), that was independent from the number of carbons of the PUFA precursor.
MS/MS spectra showed common product ions of high intensity that involved the cleavage of the
hydroxyl group (−18 m/z units = loss of H2O) and further loss of 44 m/z units (CO2) [34]. Murphy
et al. [33] have suggested that ARA hydroxides produce a type of carbon-carbon cleavage with
retention of the charge in the carboxyl group stabilized by resonance due to the high unsaturation of
the molecules. These cleavages gave rise to several common product ions for all isomers. The specific
transitions that allowed differentiating these HETEs originated from the cleavage of a carbon-carbon
bond adjacent to the hydroxyl group (α-hydroxy cleavage) at the allylic position and a transfer of one
proton to the unsaturated site [35]. We have suggested the same behavior for EPA and DHA hydroxides
on the basis of the analyzed spectra and similarities with chemical structures of ARA hydroxides.
The m/z of the resulting aldehyde and/or ketone depended on the position of the hydroxyl group
and thus it allowed unambiguous determination of the regioisomers. The aldehyde also produced
a specific fragment by a concomitant loss of 28 m/z units (loss of CO). The fragmentation pattern of
8-HETE, 12-HEPE, and 17-HDoHE as an example of hydroxides from each group are explained in
detail in Figure 2. Similar patterns were found for the other studied regioisomers whose spectra were
available at LIPID MAPS. A total of eight HETEs, seven HEPEs and ten HDoHEs were analyzed and
the corresponding fragmentations are shown in Supplementary Materials S1.
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Figure 2. Fragmentation patterns suggested for (a) ARA, (b) EPA and (c) DHA hydroxides. Common 
cleavages and specific transitions for 8-HETE, 12-HEPE and 17-HDoHE. Product ion spectra at m/z 
Figure 2. Fragmentation patterns suggested for (a) ( ) EPA and (c) DHA hydroxides. Common
cleavages and specific transitions for 8-HETE, 12- and 17-HDoHE. Product ion spectra at m/z
319 for 8HETE, m/z 317 for 12HEPE, and m/z 343 for 17HDoHE were obtained from the LIPID MAPS
database at CID 30V.
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2.2.2. Hydroperoxides
The spectra of HpETEs, HpEPEs and HpDoHEs (Figure 3 and Supplementary Materials S2)
showed a common pattern of fragmentation based on the highly reactivity of the functional group
with nearby double bonds. The characteristic fragmentation suggested was very similar to the
analogous hydroxides and independent from the number of carbons of the PUFA precursor. For
regioisomers without spectra available in database, specific fragments were hypothesized based on
the stoichiometric structure (Table 3). The loss of two molecules of H2O, CO2, and carbon-carbon
bond cuts produced a sort of common fragments between isomers. The location of the hydroperoxy
group in the chain determined the formation of characteristic fragments that allowed differentiating
the isomers of each PUFA. As for corresponding hydroxides, the α-hydroxy cleavage of carbon-carbon
bond resulted into an aldehyde with characteristic m/z and further loss of CO. Generally, most intense
fragments were produced by the α-hydroxy cleavage with stabilization of the hydroperoxyl group
in a diol structure, and then the loss of H2O and formation of an enol stabilized by resonance. A
total of seven hydroperoxide spectra were studied and specific fragments were suggested for another
seventeen isomers.
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Table 3. Hypothesized specific fragments produced from different isomers of ARA. EPA and DHA
hydroperoxides based on the chain position of –OOH group.





4-HpDoHE 101. 99. 71 121. 101. 73
7-HpDoHE 141. 139. 111 161. 141. 113
8-HpDoHE 153. 151. 123 173. 153. 125
10-HpDoHE 181. 179. 151 201. 181. 153
13-HpDoHE 221. 219. 191 241. 221. 193
14-HpDoHE 233. 231. 203 253. 233. 205
16-HpDoHE 261. 259. 231 281. 261. 233
20-HpDoHE 313. 311. 283 333. 313. 285
333 HpEPE
8-HpEPE 155. 153. 125 175. 155. 127
9-HpEPE 167. 165. 137 187. 167. 139
11-HpEPE 195. 193. 165 213. 193. 165
18-HpEPE 287. 285. 257 307. 287. 259
335 HpHETE
8-HpETE 155. 153. 125 175. 155. 127
9-HpETE 167. 165. 137 187. 167. 139
11-HpETE 195. 193. 165 213. 193. 165
19-HpETE 303. 301. 273 321. 301. 273
20-HpETE 317. 315. 287 335. 315. 287
2.2.3. Prostaglandins
The analysis of twelve spectra of type-2 prostaglandins from ARA and type-3 from EPA revealed
similar decomposition pathway behavior. Non-specific cleavages that allowed distinguishing isomers
were found according to the stereochemical structure of molecules that generally consists of a
cyclopentane ring and two side chains with carboxylic and hydroxy groups, respectively.
Intense product ions resulted from the subsequent losses up to three molecules of H2O and
losses of CO2 from intermediate ions that were produced by the cleavage of the carboxylic group and
stabilization of the charge by resonance of the hydroxyl with nearby double bonds. The carbon-carbon
cleavage in the vinylic position of the C-15 hydroxyl produced a neutral hexenal compound by a
proton transfer and several characteristic fragments with additional losses of H2O, CO2 and transfer of
protons. An intermediate carbanion produced by the α-hydroxy cleavage may produce the rupture of
the ring and stabilization by conjugate dienes of the corresponding fragment. These findings agree
with previous published descriptions of the fragmentation of the prostaglandins family [35–37]. It is
possible to unambiguously differentiate up to six groups of prostaglandins based on the parent mass
m/z: 367, 353, 351, 349, 333 and 331. However, only a good chromatographic resolution of the peaks
between isomers with the same m/z may lead to their differentiation due to their fragmentations are
virtually identical. Figure 4 and Supplementary Materials S3 graphically explain some examples of
prostaglandin fragmentation patterns.
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Figure 4. Fragmentatio patterns sugge ted for (a) PGE3, D3, (b) PGF2α. and (c) PGE2. Product ion
spectra at m/z 349, m/z 353, and m/z 351 were obtain d from the LIPID MA S database at CID 30V. An
identical sp c rum was found for PGE3 and PGD3.
2.2.4. Resolvins, Protectins and Maresins
Recent experiments have uncovered that EPA and DHA serve as precursors for the production of
potent bioactive mediators called resolvins, protectins and maresins [38]. The fragmentations of RvD1,
RvE1 and PD1 have been described in detail in Figure 5. Common fragments were produced due to
the higher unsaturation of the molecules and the number of hydroxy functional groups (up to 3) that
gave rise to many losses of H2O and CO2. Specifically. the α-cleavage of hydroxyl determined several
characteristic fragments as suggested by Serhan et al. [39]. Generally, the carbon-carbon bond was
cleaved in the vinylic position when the hydroxyl was more proximal to the end of the carbon chain;
however, it was cleaved in allylic position when proximal to the carboxylic group giving an aldehyde
ion. Further losses of H2O and CO2 were produced from intermediate fragments too. Nevertheless,
due to the novelty of these molecules, all isomers have not been widely characterized and spectra were
not available, so we have suggested possible fragments for identification of series-D and E resolvins
and MaR-1 based on the chemical structures and a similar behavior of the isomers in the decomposition
pathways (Supplementary Materials S4). The fragmentation proposed for MaR-1 was in agreement
with the mass characterization of in vitro studies reported by Dalli et al. [40].
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Figure 5. Fragmentation patterns suggested for (a,b) RvD1, (c) RvE1. and (d,e) PD1. Product ion spectra 
at m/z 375, m/z 349 and m/z 359 were obtained from the LIPID MAPS database at CID 30V. 
2.2.5. Leukotrienes, Lipoxins and Dihydroxides 
Another thirteen di-/trihydroxyeicosanoids derived from ARA and EPA have been studied and 
classified into four groups: LTs, LXs, DiHETEs and DiHETrEs. A common fragmentation pattern was 
observed, as described for resolvins and protectins, that produced common ions between isomers 
(losses of H2O and CO2). MS/MS spectra showed specific transitions depending on the location of 
hydroxy groups that were originated from α-hydroxy cleavages of adjacent carbon-carbon bonds and 
concomitant losses of H2O, CO2. and CO. The same trend as for resolvins and protectins was observed, 
with carbon-carbon cleavages generally occurring in the vinylic position of the hydroxyl located close 
to the terminal of the chain. On the contrary, the α-hydroxy cleavages proximal to the carboxylic 
group usually occurred in the allylic position. Results were in agreement with the MS/MS 
fragmentation pathways suggested by Murphy et al. [33] and Wheelan et al. [41]. 
Detailed decomposition pathways are shown in Figure 6 and Supplementary Materials S5. The 
unambiguous identification of polyhydroxy compounds resulted difficult, due to the fact they may 
produce common fragments as other eicosanoids with the same parent mass ion. That is the case of 
DiHETEs and HpHETEs (m/z 335), LXA4-B4 and some TXs and PGs (m/z 351), LXA5 and resolvins and 
some prostaglandins (m/z 351). It is also important to note that DiHETEs may produce similar 
fragmentation patterns than derived HEPEs after the initial loss of H2O. However, the different 
parent mass allows distinguishing without doubts between these two groups of similar eicosanoids. 
Figure 5. Fragmentation patterns suggested for (a,b) RvD1, (c) RvE1. and (d,e) PD1. Product ion spectra
at m/z 375, m/z 349 and m/z 359 were obtained from the LIPID MAPS database at CID 30V.
2.2.5. Leukotrienes, Lipoxins and Dihydroxides
Another thirteen di-/trihydroxyeicosanoids derived from ARA and EPA have been studied and
classified into four groups: LTs, LXs, DiHETEs and DiHETrEs. A common fragmentation pattern was
observed, as described for resolvins and protectins, that produced common ions between isomers
(losses of H2O and CO2). MS/MS spectra showed specific transitions depending on the location of
hydroxy groups that were originated from α-hydroxy cleavages of adjacent carbon-carbon bonds and
concomitant losses of H2O, CO2. and CO. The same trend as for resolvins and protectins was observed,
with carbon-carbon cleavages generally occurring in the vinylic position of the hydroxyl located close
to the terminal of the chain. On the contrary, the α-hydroxy cleavages proximal to the carboxylic group
usually occurred in the allylic position. Results were in agreement with the MS/MS fragmentation
pathways suggested by Murphy et al. [33] and Wheelan et al. [41].
Detailed decomposition pathways are shown in Figure 6 and Supplementary Materials S5. The
unambiguous identification of polyhydroxy compounds resulted difficult, due to the fact they may
produce common fragments as other eicosanoids with the same parent mass ion. That is the case of
DiHETEs and HpHETEs (m/z 335), LXA4-B4 and some TXs and PGs (m/z 351), LXA5 and resolvins
and some prostaglandins (m/z 351). It is also important to note that DiHETEs may produce similar
fragmentation patterns than derived HEPEs after the initial loss of H2O. However, the different parent
mass allows distinguishing without doubts between these two groups of similar eicosanoids.
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Figure 6. Fragmentation pattern suggested for (a) LxA4, (b) LTB4. and (c) 8.9-DiHETrE. Product ion 
spectrum at m/z 351. m/z 335. and m/z 337 were obtained from database of LIPID MAPSat CID 30V. 
2.2.6. Epoxy and Oxo-derivatives 
As described by Murphy et al. [33], epoxy derivatives of ARA (EpETrEs) showed fragmentation 
patterns very close to those of HETEs and keto derivatives of ARA showed similar fragmentations as 
HEPEs. In the case of EpETrEs, the spectra generally resulted in a mixture of the two spectra from 
HETEs with functional groups in the same locations as the epoxy group (Figure 7 and Supplementary 
Materials S6). Distinguishing some isomers from both isobaric groups—EpETrEs and HETEs—may 
be challenging if they are not chromatographically resolved because they have the same parent mass 
m/z and share most of the intense transitions. However, the epoxy LTA4 with one more unsaturation 
in the chain could be easily differentiated from HETEs and EpETrEs due to the lower m/z of the parent 
ion. The identification of some compounds from oxoETEs and HEPEs may result even more 
complicated without good chromatography resolution because they have the same parent mass and 
produce exactly the same MS/MS transitions. The main cleavages from ARA oxoETEs in Figure 8 are 
explained. Powell et al. [42] and MacMillan et al. [43] have also studied fragmentations from some 
oxo-derivatives of ARA. In a similar manner, the MS/MS spectra of several keto-PGs showed the 
same fragments as the corresponding PGs (Figure 9 and Supplementary Materials S7). However, the 
different parent mass allowed the unambiguous identification between both families. 
Figure 6. Fragmentation pattern suggested for (a) LxA4, (b) LTB4. and (c) 8.9-DiHETrE. Product ion
spectrum at m/z 351. m/z 335. and m/z 337 were obtained from database of LIPID MAPSat CID 30V.
2.2.6. Epoxy and Oxo-derivatives
As described by Murphy et al. [33], epoxy derivatives of ARA (EpETrEs) showed fragmentation
patterns very close to those of HETEs and keto derivatives of ARA showed similar fragmentations as
HEPEs. In the case of EpETrEs, the spectra generally resulted in a mixture of the two spectra from
HETEs with functional groups in the same locations as the epoxy group (Figure 7 and Supplementary
Materials S6). Distinguishing some isomers from both isobaric groups—EpETrEs and HETEs—may be
challenging if they are not chromatographically resolved because they have the same parent mass m/z
and share most of the intense transitions. However, the epoxy LTA4 with one more unsaturation in the
chain could be easily differentiated from HETEs and EpETrEs due to the lower m/z of the parent ion.
The identification of some compounds from oxoETEs and HEPEs may result even more complicated
without good chromatography resolution because they have the same parent mass and produce exactly
the same MS/MS transitions. The main cleavages from ARA oxoETEs in Figure 8 are explained. Powell
et al. [42] and MacMillan et al. [43] have also studied fragmentations from some oxo-derivatives of
ARA. In a similar manner, the MS/MS spectra of several keto-PGs showed the same fragments as the
corresponding PGs (Figure 9 and Supplementary Materials S7). However, the different parent mass
allowed the unambiguous identification between both families.
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Figure 9. Fragmentation pattern suggested for 15k-PGF2α. The product ion spectrum at m/z 351 was
obtained from the LIPID MAPS database at CID 30V.
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2.2.7. Thromboxanes
Finally, the group of thromboxanes from ARA (series 2) and EPA (series 3) showed common losses
of subsequent H2O molecules and CO2. Thromboxanes are eicosanoids structurally characterized by a
six-member ring fused between C-8 and C-12 of the fatty acid. Margalit et al. [44] have suggested that
the characteristic rupture of the ring becomes more interesting for identification of these compounds.
This cleavage produces an unstable diol structure that easily loses a H2O molecule and derived to a
more stable aldehyde [45]. The spectra and fragmentation patterns of TXB3 and TXB2 are shown in
Figure 10 and Supplementary Materials S8 and characteristic cleavages are suggested for TXA2 which
spectrum was not available.
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Firstly, compounds were searched according to the m/z of parent ion and suggested specific 
fragmentations. For the highly unstable hydroperoxides, the ionization process provoked the loss of 
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Figure 10. Fragmentation pattern suggested for TXB3. The product ion spectrum at m/z 367 was
obtained from LIPID MAPS at CID 30V.
2.3. Tentative Identifications in Samples and Validation
Once the extraction and determination procedures were validated, and fragmentation patterns
were studied, we tent tively identifi d lipid mediators in samples of plasma and adipos tissue. Firstly,
compounds were s arched according to the m/z of parent ion and suggested specific fragmentations.
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For the highly unstable hydroperoxides, the ionization process provoked the loss of H2O in the source,
then, the parent ion minus m/z 18 was also considered as the parent ion. As it was pointed out before,
the large number of isomers makes it difficult to establish a single transition for every compound that
leads to unambiguous identifications. A total of 35 compounds in adipose tissue and 30 in plasma
were tentatively identified using the diagnostic fragmentation patterns.
Next, the identification was validated using a set of standards. Up to 27 hypothetical identifications
were validated in adipose tissue and 25 in plasma. Results showed a confirmation rate of our
hypotheses of 85 and 88% in adipose tissue and plasma, respectively (4 and 3 proposed identifications
failed, respectively).
Specifically, the presence of nine isomers in adipose tissue and seven in plasma from the family of
HEPEs and oxoETEs was observed on the basis of the screening analysis of m/z 317. We tentatively
identified 18-HEPE, 15-HEPE, 12-HEPE, 11-HEPE, 5-HEPE and 12-oxoETE in both samples and their
presence was confirmed by using commercial standards. Specific and common cleavages were found
for these compounds according to the rules described above. In addition, an increase in the retention
time of hydroxides was observed when the position of hydroxyl was more proximal to the carboxylic
group. This fact may be explained by a decrease in the polarity of the molecule. However, there were
exceptions to this rule between 11-HEPE and 12-HEPE, 11-HETE and 12-HETE and 13-HDoHE and
14-HDoHE in agreement with Massey et al. [1]. 9-HEPE was suggested in adipose tissue although it
was not validated. The isomers 5-oxoETE in both samples and 15-oxoETE in adipose were suggested.
However, validation experiments showed non-coincidence of the retention times between standards
and the hypothetical peaks.
Similarly, the presence of 15-HETE, 12-HETE, 11-HETE and 14.15-EpETE in both samples was
suggested based on the screening analysis of m/z 319. 11.12-EpETE was only suggested in adipose
tissue and 20-HETE in plasma. In addition, one peak was found in both samples leading to theoretical
identification of 5.6-EpETE or 5-HETE. They cannot be unambiguously identified without retention
time information due to similarities in the mass spectra and specific transitions. The use of 5-HETE
standard confirmed the absence of this compound in samples. Additionally, it was observed that epoxy
and hydroxy isomers with concurrent positions of functional groups did not co-elute under our LC
conditions. Therefore a peak attributed either to 5-HETE or 5.6-EpETE was tentatively identified and
then validated as the epoxy isomer.
Special attention was required for hydroperoxides from DHA (HpDoHE) (m/z 359), EPA (HpEPE)
(m/z 333), and ARA (HpETE) (m/z 335). These compounds were found to display higher sensitivity
using the ratios m/z 341, m/z 315 and m/z 317 as parent mass filter, respectively. In spite of the low-energy
ionization used, hydroperoxides may lose a H2O molecule in the ESI source due to the low stability of
the hydroperoxy group. Therefore, specific transitions for these compounds were searched for in the
chromatogramf using both “parent mass” ratios. We could not confirm the hypothesis of the presence
of HpDoHEs and HpETEs based on common and specific transitions. However, the use of commercial
17-HpDoHE showed its presence in both samples although it had not been previously hypothesized.
The presence of 12-HpEPE was suggested and further validated in plasma.
Regarding DHA hydroxides, the analysis of m/z 343 showed a hypothetical identification of eight
isomers in adipose tissue and six isomers in plasma based on specific transitions. Standards validation
confirmed four hydroxides in adipose and three in plasma. No false identifications were seen in
this group. In the same way. 335 m/z was analyzed searching for DiHETEs from ARA. Six isomers
were tentatively found in adipose tissue and five in plasma, from which two were confirmed and one
rejected by using standards. Then, the presence of PGE2/PGD2, ARA, EPA and DHA was suggested in
both samples by analyzing m/z 351, 303, 301 and 327 parent mass ions, respectively, and the hypotheses
were confirmed. Finally, 14.15-DiHETrE was hypothesized in adipose tissue based on 337 m/z screening
and it was validated.
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Seven other m/z ratios were also detected but their fragmentation pattern could not be assigned to
any of the groups studied (624, 375, 369, 367, 353, 349 and 331). Results for tentative identifications and
validations are summarized in Table 4, along with information about specific transitions.
Table 4. Compounds tentatively identified in adipose tissue and plasma, validation with standards
and specific transitions used for our hypothetical identifications.



















18-HEPE confirmation 18-HEPE confirmation 287. 259
15-HEPE confirmation 15-HEPE confirmation 247. 219
12-HEPE confirmation 12-HEPE confirmation 207. 179
11-HEPE confirmation 11-HEPE confirmation 195. 167
9-HEPE 167. 139
5-HEPE confirmation 5-HEPE confirmation 115. 87
12-oxoETE confirmation 12-oxoETE confirmation 207. 179. (153)
15-oxoETE rejection 247. 219. (113)
5-oxoETE rejection 5-oxoETE rejection 115. 87. (203)
319
20-HETE confirmation 317. 289. (245)
15-HETE confirmation 15-HETE confirmation 247. 219
12-HETE confirmation 12-HETE confirmation 207. 179
11-HETE confirmation 11-HETE confirmation 195. 167
5-HETE rejection 5-HETE rejection 115. 87
5.6-EpETrE confirmation 5.6-EpETrE confirmation 115. 87
11.12-EpETrE confirmation 207. 179. 167
14.15-EpETrE confirmation 14.15-EpETrE confirmation 249. 221. 207
343
20-HDoHE 20-HDoHE 313. 285. (187)
17-HDoHE confirmation 17-HDoHE confirmation 273. 245
16-HDoHE 261. 233
14-HDoHE confirmation 14-HDoHE confirmation 233. 205
13-HDoHE 13-HDoHE 221. 193
11-HDoHE confirmation 193. 165. (149)
10-HDoHE 181. 153
8-HDoHE 153. 125. (189). (109)
4-HDoHE confirmation 4-HDoHE confirmation 115. 101. 73
359-341 17HpDoHE 17HpDoHE 297
335
8.15-DiHETE 265. 155
14.15-DiHETE confirmation 14.15-DiHETE confirmation 265. 219. 247. 207
5.12-DiHETE=LTB4 rejection 5.12-DiHETE=LTB4 rejection 195. 129
11.18-DiHETE 11.18-DiHETE 289. 165. 193
5.6-DiHETE confirmation 5.6-DiHETE confirmation 115. (145)
11.12-DiHETE 11.12-DiHETE 234. 222. 193. 165
333-315 12-HpEPE confirmation 207. 227. 179
351 PGE2-PGD2 confirmation PGE2-PGD2 confirmation 251
303 ARA confirmation ARA confirmation 259
301 EPA confirmation EPA confirmation 257
327 DHA confirmation DHA confirmation 283
337 14-15DiHETrE confirmation 207. 129
3. Experimental Section
3.1. Chemicals
Thromboxane B3 (TXB3), prostaglandin D3 (PGD3), prostaglandin E3 (PGE3),
prostaglandin D2 (PGD2), prostaglandin E2 (PGE2), prostaglandin B2 (PGB2), prostaglandin
J2 (PGJ2), resolvin D1 (RvD1), resolvin D2 (RvD2), maresin R1 (MaR1), protectin Dx (PDx,
10(S),17(S)-dihydroxy-4Z,7Z,11E,13Z,15E,19Z-docosahexaenoic acid), leukotriene B4 (LTB4),
leukotriene C4 (LTC4), isoprostane F2α (8isoPGF2α), isoprostane F3α (8isoPGF3α), 15-HpEPE
(15(S)-hydroperoxy-5Z,8Z,11Z,13E,17Z-eicosapentaenoic acid), 12-HpEPE (12(S)-hydroperoxy-
5Z,8Z,10E,14Z,17Z-eicosapentaenoic acid), 15-HpETE (15(S)-hydroperoxy-5Z,8Z,11Z,13E-
eicosatetraenoic acid), 12-HpETE (±12-hydroperoxy-5Z,8Z,10E,14Z-eicosatetraenoic acid),
5-HpETE (5(S)-hydroperoxy-6E,8Z,11Z,14Z-eicosatetraenoic acid), 17-HpDoHE (17(S)-hydroperoxy-
4Z,7Z,10Z,13Z,15E,19Z-docosahexaenoic acid), 18-HEPE (±18-hydroxy-5Z,8Z,11Z,14Z,16E-eicosa-
pentaenoic acid), 15-HEPE (±15-hydroxy-5Z,8Z,11Z,13E,17Z-eicosapentaenoic acid), 12-HEPE
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(±12-hydroxy-5Z,8Z,10E,14Z,17Z-eicosapentaenoic acid), 11-HEPE (±11-hydroxy-5Z,8Z,12E,14Z,
17Z-eicosapentaenoic acid), 5-HEPE (±5-hydroxy-6E,8Z,11Z,14Z,17Z-eicosapentaenoic acid),
17,18-DiHETE (±17,18-dihydroxy-5Z,8Z,11Z,14Z-eicosatetraenoic acid), 17,18-EpETE (±17,18-epoxy-
5Z,8Z,11Z,14Z-eicosatetraenoic acid), 11,12-EpETE (±11,12-epoxy-5Z,8Z,14Z,17Z-eicosatetraenoic
acid), 14,15-EpETE (±14,15-epoxy-5Z,8Z,11Z,17Z-eicosatetraenoic acid), 8,9-EpETE (±8,9-epoxy-
5Z,11Z,14Z,17Z-eicosatetraenoic acid), 20-HETE (±20-hydroxy-5Z,8Z,11Z,14Z-eicosatetraenoic acid),
15-HETE (±15-hydroxy-5Z,8Z,11Z,13E-eicosatetraenoic acid), 12-HETE (±12-hydroxy-5Z,8Z,10E,
14Z-eicosatetraenoic acid), 11-HETE (±11-hydroxy-5Z,8Z,12E,14Z-eicosatetraenoic acid), 5-HETE
(±5-hydroxy-6E,8Z,11Z,14Z-eicosatetraenoic acid), 14,15-DiHETE (±14,15-dihydroxy-5Z,8Z,11Z,
17Z-eicosatetraenoic acid), 5,15-DiHETE (5(S),15(S)-dihydroxy-6E,8Z,10Z,13E-eicosatetraenoic
acid), 5,6-DiHETE (±5,6-dihydroxy-8Z,11Z,14Z,17Z-eicosatetraenoic acid), 11,12-DiHETrE (±11,12-
dihydroxy-5Z,8Z,14Z-eicosatrienoic acid), 11,12-EpETrE (±11,12-epoxy-5Z,8Z,14Z-eicosatrienoic
acid), 8,9-DiHETrE (±8,9-dihydroxy-5Z,11Z,14Z-eicosatrienoic acid), 8,9-EpETrE (±8,9-epoxy-
5Z,11Z,14Z-eicosatrienoic acid), 14,15-DiHETrE (±14,15-dihydroxy-5Z,8Z,11Z-eicosatrienoic acid),
14,15-EpETrE (±14,15-epoxy-5Z,8Z,11Z-eicosatrienoic acid), 5,6-DiHETrE (±5,6-dihydroxy-8Z,11Z,
14Z-eicosatrienoic acid), 5,6-EpETrE (±5,6-epoxy-8Z,11Z,14Z-eicosatrienoic acid), 17-HDoHE
(±17-hydroxy-4Z,7Z,10Z,13Z,15E,19Z-docosahexaenoic acid), 14-HDoHE (14(S)-hydroxy-4Z,7Z,
10Z,12E,16Z,19Z-docosahexaenoic acid), 11-HDoHE (±11-hydroxy-4Z,7Z,9E,13Z,16Z,19Z-
docosahexaenoic acid), 4-HDoHE (±4-hydroxy-5E,7Z,10Z,13Z,16Z,19Z-docosahexaenoic acid),
19,20-DiHDPA (±19,20-dihydroxy-4Z,7Z,10Z,13Z,16Z-docosapentaenoic acid), 19,20-EDP (±19,20-
epoxy-4Z,7Z,10Z,13Z,16Z-docosapentaenoic acid), 7(S)-17(S)dihydroxy-8E,10Z,13Z,15E,19Z-
docosapentaenoic acid), 10,11-EDP (±10,11-epoxy-4Z,7Z,13Z,16Z,19Z-docosapentaenoic acid),
16,17-EDP (±16,17-epoxy-4Z,7Z,10Z,13Z,19Z-docosapentaenoic acid), 7,8-EDP (±7,8-epoxy-4Z,10Z,
13Z,16Z,19Z-docosapentaenoic acid), 13,14-EDP (±13,14-epoxy-4Z,7Z,10Z,16Z,19Z-docosa-
pentaenoic acid), 15-oxoETE (15-oxo-5Z,8Z,11Z,13E-eicosatetraenoic acid), 12oxoETE
(12-oxo-5Z,8Z,10E,14Z-eicosatetraenoic acid), 5-oxoETE (5-oxo-6E,8Z,11Z,14Z-eicosatetraenoic
acid), 12-HETE-d8 (12(S)-hydroxy-5Z,8Z,10E,14Z-eicosatetraenoic-5,6,8,9,11,12,14,15-d8 acid), EPA
(5Z,8Z,11Z,14Z,17Z-eicosapentaenoic acid), DHA (4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoic acid), and
ARA (5Z,8Z,11Z,14Z-eicosatetraenoic acid) were purchased from Cayman Chemicals (Ann Arbor, MI,
USA). The supplier stated purities higher than 96% for all standards. Methanol and water, Optima LC-MS
grade, were purchased from Fisher Scientific (Branchburg, NJ, USA); methyl formate was purchased from
Sigma Aldrich (Poole, UK); n-Hexane was provided by Merck (Darmstadt, Germany) and ethanol, formic
acid and hydrochloric acid were from AnalR Normapur (Fontenai, France). SPE cartridges (Oasis-HLB,
60 mg, 3 mL) were supplied by Waters (Milford, MA, USA).
3.2. Plasma and Adipose Tissue Samples
Blood from Wistar rats from a previous experiment was collected and centrifuged at 850 g (4 ◦C,
15 min) in the presence of EDTA to remove erythrocytes. Then, plasma was supplemented with
5 mM phenyl methyl sulfonyl fluoride (PMSF, protease inhibitor) and erythrocyte free samples were
immediately stored at −80 ◦C until use. The defrosting process was carried out slowly in darkness, to
prevent possible analyte oxidation and degradation [46]. Total abdominal fat, corresponding to the
sum of epididymal, perirenal and mesenteric depots was excised, washed with 0.9% NaCl solution,
weighed and immediately frozen in liquid nitrogen upon sacrifice.
3.3. Sample Preparation by Solid Phase Extraction
Lipid mediators from plasma samples were extracted following a modified SPE method previously
described [47]. Briefly, 1300 µL of cold methanol: water (30:70, v/v) was used to extract metabolites
from 200 µL of spiked plasma with internal standard 12-HETE-d8 (500 ng/mL). After centrifugation,
remaining solution was loaded into conditioned Oasis-HLB cartridges (60 mg, 3 mL, Waters, Milford,
MA, USA) with 5 mL methanol (0.5% BHT) and 5 mL water in succession. Then, cartridges were
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washed with 5 mL cold water, 5 mL cold methanol: water (15:75, v/v), and 2.5 mL cold hexane in
succession. After sorbent dryness, compounds were eluted with 2 mL of cold methyl formate (0.1%
BHT). Extracts were evaporated to dryness in a speed-Vacuum system from Supelco (Bellefonte, PA,
USA) coupled to a vacuum pump from Millipore (Bedford, MA, USA). The residue was dissolved in
30 µL cold ethanol and stored at −80 ◦C prior to LC-MS/MS analysis.
Metabolites from adipose tissue were extracted using a modified method of a published
protocol [48]. 150 mg of frozen tissues were cut, spiked with internal standard 12-HETE-d8 and
extracted by adding 1 mL cold-methanol (0.5% BHT) and sonication for 1min under 0.6 sec cycle and
100% of amplitude (Labsonic sonicator from Sartorius, city, Germany). Samples were incubated on ice
for 10 min and then centrifuged at 800 g for 10 min, at 4 ◦C, to remove potential proteins that may
cause interference. Supernatant was transferred to a clean amber glass vial and pellet was subjected
to a second extraction in methanol and sonication as described. Both supernatants were collected
together and final pellet was washed with 500 µL cold methanol: water (30:70, v/v) twice. The pooled
fractions were diluted with 4.6 mL of cold water to a final solution of methanol: water (30:70, v/v).
Then, samples were loaded to SPE cartridges following the same procedure as plasma samples.
3.4. LC-MS/MS
Chromatographic separation was carried out on a Dionex UltiMate 3000 Series (Thermo Fisher,
Rockford, IL, USA) that includes a binary pump, a degasser system and a thermostated autosampler.
Compounds were separated on a C18-Symmetry column, 150 × 2.1 mm, 3.5 µm (Waters) protected with
a 4 × 2mm C18 guard cartridge provided by Phenomenex (Torrance, CA, USA). A binary eluent system
of water (A) and methanol (B), both with 0.02% (v/v) of formic acid, was used as mobile phase. The
gradient was: 0–1 min (60% B), 2–12 min (80% B), 13–18 min (100% B), and 19–24 min (60% B). The flow
rate was set to 0.2 mL/min, the column effluent was directly introduced in the ESI interface without
splitting, and injection volume was set to 10 µL. The column was maintained at room temperature
and extracts were kept at 4 ◦C in the autosampler. Mass spectrometry analyses were carried out on a
dual-pressure linear ion trap LTQ Velos Pro (Thermo Fisher). Operating conditions of the ESI source
were negative ion mode with a sheath gas flow rate of 40 units, spray voltage of 5.5 kV, capillary
temperature of 300 ◦C and S-lens radio-frequency level of 60%. Nitrogen was used as nebulizing gas
and helium was the collision gas. Instrument control and data acquisition were done with Xcalibur
software. Compounds were divided into 22 groups according to the m/z of their parent ion. Acquisition
was set as full scan mode ranged from 90 to 400 m/z units with the 22 parent masses in a single segment
during the whole run. The isolation width was set at 1. Collision energies for each m/z are summarized
in Table 5 and they were set as a compromise among the most common used in literature and optimized
collision energies for 65 analytical standards used for validation purposes.
Table 5. MS/MS conditions of the non-targeted LC-MS/MS method developed. More than 100
compounds were classified in 22 groups according to the m/z of their parent ions in negative ESI.
Compromise collision energies used for each m/z are shown. The families of lipid mediators studied in
each parent mass of the method are indicated as well as some examples of metabolites.
Parent Mass (m/z) Collision Energy (V) Family of LipidMediators Some Examples
301.0 25 PUFAs-ω3 EPA
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Table 5. Cont.




326.0 27 internal standard 12-HETE-d8
327.0 27 PUFA-ω3 DHA
331.0 30 PGs PGA3. PGB3




335.0 & 317.0 30 HpETEs 11-HpETE. 12-HpETE
335.0 30 DiHETEs 5.12-DiHETE.17.18-DiHETE









PGs. k-PGs PGE2. PGF3α.15k-PGF2α
TXs TXA2
LXs LXA4. LXB4
353.0 30 PGs. k-PGs PGF2α. 15k-PGF1α




361.0 28 DiHDPAs 19.20-DiHDPA
367.0 20





375.0 27 Rvs RvD1. RvD2
624.0 26 LTs LTC4
3.5. Method Validation: Linearity. Repeatability. Reproducibility. LOD. LOQ. Recovery Experiments. and
Matrix Effect
Eight batches of calibration solutions were used to determine the dynamic linear range of response
for each of the 65 analytical standards in the range between 1 and 1000 ng/mL, with the exception
of ARA. EPA and DHA, whose concentration in biological samples is higher, and thus linearity was
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evaluated in the range between 0.1 and 50 µg/mL. The calibration curves were calculated using
least-squares linear regression. The internal standard (12-HETE-d8) was included in all calibration
solutions at 500 ng/mL. The reproducibility (inter-day) and repeatability (intra-day) of the instrument
was evaluated at three levels of concentration (n = 4) for each compound: 1, 50, and 1000 ng/mL; and
0.1, 10, 50 µg/mL for PUFAs, LODs and LOQs were estimated by using signal-to-noise (S/N) ratios of 3
and 10, respectively.
Different recovery experiments were performed to determine global recovery, SPE recovery and
matrix effects: (a) The percentage of global recovery was evaluated comparing the signal for each
metabolite between: spiked plasma and adipose tissue samples before preparation and a pool of
analytical standards at the same level of concentration. (b) The percentage of SPE recovery was
determined comparing samples spiked before preparation with samples spiked after the SPE step.
(c) Matrix effect was evaluated comparing samples spiked after the SPE extraction with the pool of
analytical standards. In any case, when metabolites were already present in blank samples (non-spiked
samples), the area of chromatographic peaks in spiked samples was subtracted with the area in blanks.
Experiments were done in triplicate and the repeatability of the entire method was expressed as
percentage of relative standard deviation (%RSD).
3.6. Qualitative Screening of Samples and Validation
Plasma and adipose tissue were subjected to SPE-LC-MS/MS. Chromatographic peaks for each
parent mass were extracted from MS2 selecting quantitative and selective transitions for each
lipid mediator according to the fragmentation pattern previously studied. The spectra of each
chromatographic peak was studied and compared with the fragmentation pattern to tentatively
identify compounds in samples. Then, other samples were spiked before extraction with a pool of 65
standards described in the chemical section. Spiked samples were analyzed under the same LC-MS/MS
conditions than non-spiked ones and hypothetical identifications were validated using the information
of retention times and fragmentation in standards and samples.
3.7. Data Analysis
Means, standard deviations, least-squares linear regression curves, and percentages used to
validate methodology were performed by using the free R software (version 3.2.4).
4. Conclusions
An extensive study of fragmentation patterns provided fingerprints allowing us to
comprehensively elucidate and identify lipid mediators in biological samples obtained by
SPE-LC-MS/MS analysis. It has allowed the identification of over 100 bioactive ω-6 and ω-3
metabolites. Interestingly, illustrative fragmentations of EPA and DHA derivatives have been
innovatively established for successful identification. The fragmentation patterns study could be
used for developing software in order to facilitate the identification of this big family of metabolites
without the need of standards for qualitative purposes. The screening method was useful to correctly
identify more than 85% of the compounds found in biological samples using the fragmentation patterns
here proposed. Moreover, the method allowed the identification of these metabolites without losing
information by the use of predefined ions list. Few works proposing MS/MS screening methods
to analyze lipid mediators have been found in literature. In our study, we suggested new specific
transitions to identify lipid mediators, especially for those derived from EPA and DHA and we achieved
a high success score in identifications by using a LIT without the high mass resolution of an Orbitrap.
Further improvements of these techniques are needed in order to increase the number of target
metabolites that can be accurately identified in a single screening step before the quantitative analysis.
Supplementary Materials: The following are available online. Supplementary Materials S1: Common and
specific transitions suggested for hydroxy-derivates from ARA, EPA and DHA. Product ion spectrum at m/z 319
for HETEs, m/z 317 for HEPEs, and m/z 343 for HDoHEs were obtained from database of LIPID MAPS at CID 30V.
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No spectra was found for 19-HETE. Supplementary Materials S2: Common and specific transitions suggested for
12 and 15 hydroperoxy-derivates of ARA and EPA. Product ion spectrum at m/z 335 for HpETEs, and m/z 333 for
HpEPEs were obtained from database of LIPID MAPS at CID 30V. Supplementary Materials S3: Fragmentation
pattern suggested for prostaglandins derived from ARA and EPA. Product ion spectrum at m/z 331, m/z 333, m/z
351, and m/z 367 were obtained from database of LIPID MAPS at CID 30V. Supplementary Materials S4: Possible
fragments for identification of RvD2, RvD3, RvD4, RvE2, and MaR-1. Supplementary Materials S5: Fragmentation
pattern suggested for LxB4 (product ion spectrum at m/z 351 [33]), and several DiHETEs and DiHETrEs (product
ion spectrum at m/z 335 and m/z 337 obtained from LIPID MAPS at CID 30V). MS/MS spectrum was not found for
LxA5, 8,15-DiHETE, 14,15-DiHETE, and 17,18-DiHETE; thus, possible fragments for identification were suggested
based on lipid structure. Supplementary Materials S6: Fragmentation pattern suggested for EpETrE isomers and
LTA4. Product ion spectrum at m/z 319 were obtained from database of LIPID MAPS at CID 30V, and m/z 317
was obtained from Murphy et al [33]. Supplementary Materials S7: Fragmentation pattern suggested for several
keto-PGs. Product ion spectrum at m/z 349, m/z 351, m/z 353, m/z 367, and m/z 369 were obtained from database of
LIPID MAPS at CID 30V. Supplementary Materials S8: Fragmentation pattern suggested for TXB2 and TXA2. The
product ion spectrum at and m/z 369 was obtained from LIPID MAPS at CID 30V. Characteristic MS/MS transitions
were suggested for TXA2 based on lipid structure.
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